Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Horvath

Showing results (191-200 of 279) with videos related to

Pageof 28
Sort By:
The American Journal of Cardiology|May 21, 2008
Impact of body mass index on the one-year clinical outcome of patients undergoing multivessel revascularization with sirolimus-eluting stents (from the Arterial Revascularization Therapies Study Part II)Ahmed A Khattab, Joost Daemen, Gert Richardt, et al.
JCO Oncology Practice|September 24, 2020
Evaluation of a Mainstream Model of Genetic Testing for Men With Prostate CancerTahlia Scheinberg, Annabel Goodwin, Emilia Ip, et al.
BJU International|October 14, 2011
High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapyRichard Savdie, Lisa G Horvath, Ruth Pe Benito, et al.
Oncogene|August 8, 2012
Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancerT Hulf, T Sibbritt, E D Wiklund, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2004
Membranous expression of secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC3 cellular proliferation in vitroLisa G Horvath, Susan M Henshall, James G Kench, et al.
Ebiomedicine|April 9, 2020
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancerManish Kohli, Winston Tan, Tiantian Zheng, et al.
European Urology Focus|December 19, 2025
Strategies to Mitigate Breast-related Adverse Events in Patients with High-risk Biochemically Recurrent Prostate Cancer Receiving Enzalutamide Monotherapy: Perspectives and ChallengesNeal D Shore, Stephen J Freedland, Lisa G Horvath, et al.
The Prostate|November 15, 2017
Altered mitochondrial genome content signals worse pathology and prognosis in prostate cancerAnton M F Kalsbeek, Eva K F Chan, Judith Grogan, et al.
Aging|October 6, 2016
Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancerAnton M F Kalsbeek, Eva F K Chan, Judith Grogan, et al.
Cancer Research|September 24, 2009
Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profilingLiangli Zhao, Brian Y Lee, David A Brown, et al.
Pageof 28

Showing results (191-200 of 279) with videos related to

Sort By:
Pageof 28
The American Journal of Cardiology|May 21, 2008
Impact of body mass index on the one-year clinical outcome of patients undergoing multivessel revascularization with sirolimus-eluting stents (from the Arterial Revascularization Therapies Study Part II)Ahmed A Khattab, Joost Daemen, Gert Richardt, et al.
JCO Oncology Practice|September 24, 2020
Evaluation of a Mainstream Model of Genetic Testing for Men With Prostate CancerTahlia Scheinberg, Annabel Goodwin, Emilia Ip, et al.
BJU International|October 14, 2011
High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapyRichard Savdie, Lisa G Horvath, Ruth Pe Benito, et al.
Oncogene|August 8, 2012
Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancerT Hulf, T Sibbritt, E D Wiklund, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2004
Membranous expression of secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC3 cellular proliferation in vitroLisa G Horvath, Susan M Henshall, James G Kench, et al.
Ebiomedicine|April 9, 2020
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancerManish Kohli, Winston Tan, Tiantian Zheng, et al.
European Urology Focus|December 19, 2025
Strategies to Mitigate Breast-related Adverse Events in Patients with High-risk Biochemically Recurrent Prostate Cancer Receiving Enzalutamide Monotherapy: Perspectives and ChallengesNeal D Shore, Stephen J Freedland, Lisa G Horvath, et al.
The Prostate|November 15, 2017
Altered mitochondrial genome content signals worse pathology and prognosis in prostate cancerAnton M F Kalsbeek, Eva K F Chan, Judith Grogan, et al.
Aging|October 6, 2016
Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancerAnton M F Kalsbeek, Eva F K Chan, Judith Grogan, et al.
Cancer Research|September 24, 2009
Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profilingLiangli Zhao, Brian Y Lee, David A Brown, et al.
Pageof 28